drug: valproate
U.S. Preparations:
- Depacon® injectable (Abbott Laboratories) FDA approved:
12.30.1996
as an intravenous alternative in patients for whom oral administration of
valproate products is temporarily not feasible in the following conditions:
monotherapy and adjunctive therapy in the treatment of patients with complex
partial seizures that occur either in isolation or in association with other
types of seizures; as sole and adjunctive therapy in the treatment of patients
with simple and complex absence seizures, and adjunctively in patients with
multiple seizure types that include absence seizures
WARNING
U.S. Prescribing Information
- Depakene® (Abbott Laboratories) FDA approved:
2.28.78 for treatment of epilepsy
WARNING
- Stavzor™ (Banner) FDA approved:
7.29.2008 Acute treatment of manic episodes associated with bipolar disorder;
Monotherapy and adjunctive therapy of complex partial seizures and simple and
complex absence seizures; adjunctive therapy in patients with multiple seizure
types that include absence seizures; Prophylaxis of migraine headaches
U.S. Prescribing Information
Preparations Outside U.S.:
- Absenor, Apilepsin, Convulex, Convulsofin, Delepsine,
Depakin, Depakine, Deparkin, Deprakine, Dipromal, Epilim, Ergenyl, Everiden,
Hydoic acid, Leptilan, Leptilanil, Leptilen, Mylproin, Orfilept, Orfiril,
Propymal, Valcote, Valparine, Varpro, Vupral
|
